Standard

Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma. / Egorova, Anna; Shtykalova, Sofia; Selutin, Alexander; Shved, Natalia; Maretina, Marianna; Selkov, Sergei; Baranov, Vladislav; Kiselev, Anton.

в: Pharmaceutics, Том 13, № 2, 202, 02.2021, стр. 1-27.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Egorova, A, Shtykalova, S, Selutin, A, Shved, N, Maretina, M, Selkov, S, Baranov, V & Kiselev, A 2021, 'Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma', Pharmaceutics, Том. 13, № 2, 202, стр. 1-27. https://doi.org/10.3390/pharmaceutics13020202

APA

Egorova, A., Shtykalova, S., Selutin, A., Shved, N., Maretina, M., Selkov, S., Baranov, V., & Kiselev, A. (2021). Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma. Pharmaceutics, 13(2), 1-27. [202]. https://doi.org/10.3390/pharmaceutics13020202

Vancouver

Egorova A, Shtykalova S, Selutin A, Shved N, Maretina M, Selkov S и пр. Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma. Pharmaceutics. 2021 Февр.;13(2):1-27. 202. https://doi.org/10.3390/pharmaceutics13020202

Author

Egorova, Anna ; Shtykalova, Sofia ; Selutin, Alexander ; Shved, Natalia ; Maretina, Marianna ; Selkov, Sergei ; Baranov, Vladislav ; Kiselev, Anton. / Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma. в: Pharmaceutics. 2021 ; Том 13, № 2. стр. 1-27.

BibTeX

@article{30a372a2931d4ddfba179131f25f6861,
title = "Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma",
abstract = "Uterine leiomyoma (UL) is one of the most common benign tumors in women that often leads to many reproductive complications. Suicide genetherapy was suggested as a promising approach for UL treatment. In the present study, we describe iRGD ligand-conjugated cysteine-rich peptide carrier RGD1-R6 for targeted DNA delivery to αvβ3 integrin-expressing primary UL cells. The physico-chemical properties, cytotoxicity, transfection efficiency and specificity of DNA/RGD1-R6 polyplexes were investigated. TheHSV-1thymidine kinase encoding plasmid delivery to PANC-1pancreatic carcinoma cells and primary UL cells resulted in significant suicide gene therapy effects. Subsequent ganciclovir treatment decreased cells proliferative activity, induced of apoptosis and promoted cells death.The obtained results allow us to concludethatthe developed RGD1-R6 carrier can be considered a promising candidate for suicide gene therapy of uterine leiomyoma.",
keywords = "DNA delivery, Gene therapy, IRGD, Integrins, Pancreatic carcinoma, Peptide-based carriers, Thymidine kinase, Uterine leiomyoma, thymidine kinase, gene therapy, peptide-based carriers, integrins, pancreatic carcinoma, iRGD, uterine leiomyoma",
author = "Anna Egorova and Sofia Shtykalova and Alexander Selutin and Natalia Shved and Marianna Maretina and Sergei Selkov and Vladislav Baranov and Anton Kiselev",
note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = feb,
doi = "10.3390/pharmaceutics13020202",
language = "English",
volume = "13",
pages = "1--27",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "MDPI AG",
number = "2",

}

RIS

TY - JOUR

T1 - Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma

AU - Egorova, Anna

AU - Shtykalova, Sofia

AU - Selutin, Alexander

AU - Shved, Natalia

AU - Maretina, Marianna

AU - Selkov, Sergei

AU - Baranov, Vladislav

AU - Kiselev, Anton

N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/2

Y1 - 2021/2

N2 - Uterine leiomyoma (UL) is one of the most common benign tumors in women that often leads to many reproductive complications. Suicide genetherapy was suggested as a promising approach for UL treatment. In the present study, we describe iRGD ligand-conjugated cysteine-rich peptide carrier RGD1-R6 for targeted DNA delivery to αvβ3 integrin-expressing primary UL cells. The physico-chemical properties, cytotoxicity, transfection efficiency and specificity of DNA/RGD1-R6 polyplexes were investigated. TheHSV-1thymidine kinase encoding plasmid delivery to PANC-1pancreatic carcinoma cells and primary UL cells resulted in significant suicide gene therapy effects. Subsequent ganciclovir treatment decreased cells proliferative activity, induced of apoptosis and promoted cells death.The obtained results allow us to concludethatthe developed RGD1-R6 carrier can be considered a promising candidate for suicide gene therapy of uterine leiomyoma.

AB - Uterine leiomyoma (UL) is one of the most common benign tumors in women that often leads to many reproductive complications. Suicide genetherapy was suggested as a promising approach for UL treatment. In the present study, we describe iRGD ligand-conjugated cysteine-rich peptide carrier RGD1-R6 for targeted DNA delivery to αvβ3 integrin-expressing primary UL cells. The physico-chemical properties, cytotoxicity, transfection efficiency and specificity of DNA/RGD1-R6 polyplexes were investigated. TheHSV-1thymidine kinase encoding plasmid delivery to PANC-1pancreatic carcinoma cells and primary UL cells resulted in significant suicide gene therapy effects. Subsequent ganciclovir treatment decreased cells proliferative activity, induced of apoptosis and promoted cells death.The obtained results allow us to concludethatthe developed RGD1-R6 carrier can be considered a promising candidate for suicide gene therapy of uterine leiomyoma.

KW - DNA delivery

KW - Gene therapy

KW - IRGD

KW - Integrins

KW - Pancreatic carcinoma

KW - Peptide-based carriers

KW - Thymidine kinase

KW - Uterine leiomyoma

KW - thymidine kinase

KW - gene therapy

KW - peptide-based carriers

KW - integrins

KW - pancreatic carcinoma

KW - iRGD

KW - uterine leiomyoma

UR - http://www.scopus.com/inward/record.url?scp=85100822911&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/d5fc8db1-1f35-31c1-b51b-74ee2c0e8c4d/

U2 - 10.3390/pharmaceutics13020202

DO - 10.3390/pharmaceutics13020202

M3 - Article

C2 - 33540912

VL - 13

SP - 1

EP - 27

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 2

M1 - 202

ER -

ID: 87519780